Success Metrics

Clinical Success Rate
88.9%

Based on 24 completed trials

Completion Rate
89%(24/27)
Active Trials
2(6%)
Results Posted
38%(9 trials)
Terminated
3(8%)

Phase Distribution

Ph phase_2
10
28%
Ph not_applicable
3
8%
Ph phase_1
1
3%
Ph phase_4
8
22%
Ph phase_3
8
22%

Phase Distribution

1

Early Stage

10

Mid Stage

16

Late Stage

Phase Distribution30 total trials
Phase 1Safety & dosage
1(3.3%)
Phase 2Efficacy & side effects
10(33.3%)
Phase 3Large-scale testing
8(26.7%)
Phase 4Post-market surveillance
8(26.7%)
N/ANon-phased studies
3(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

24 of 28 finished

Non-Completion Rate

14.3%

4 ended early

Currently Active

2

trials recruiting

Total Trials

36

all time

Status Distribution
Active(2)
Completed(24)
Terminated(4)
Other(6)

Detailed Status

Completed24
unknown6
Terminated3
Recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
36
Active
2
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (3.3%)
Phase 210 (33.3%)
Phase 38 (26.7%)
Phase 48 (26.7%)
N/A3 (10.0%)

Trials by Status

recruiting26%
unknown617%
withdrawn13%
completed2467%
terminated38%

Recent Activity

Clinical Trials (36)

Showing 20 of 36 trialsScroll for more
NCT05421858Phase 3

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

Recruiting
NCT04961593

PK/PD of Caspofungin in Children Severe Infection

Recruiting
NCT00413218Phase 3

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

Completed
NCT01058174Phase 3

Liver Transplant European Study Into the Prevention of Fungal Infection

Completed
NCT00839540Phase 4

Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins

Completed
NCT03399032

Pharmacokinetics of Caspofungin

Completed
NCT03667690Phase 3

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

Completed
NCT03857399Phase 2

Empiric Therapy of Patients With Persistent Fever and Agranulocytosis Using Caspofungin

Completed
NCT02734862Phase 2

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

Completed
NCT01533558

Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates

Completed
NCT02603575Not Applicable

Effects and Safety of Caspofungin and Corticosteroids in Pneumocystis Pneumonia in Non-HIV Patients

Unknown
NCT01945281Phase 2

Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)

Terminated
NCT03978559Phase 4

Trimethoprim/Sulfamethoxazole Combined With Caspofungin as First-line Therapy in PCP

Unknown
NCT02596984Not Applicable

Evaluation of the Pharmacokinetics of Caspofungin in ICU Patients

Completed
NCT02895529Phase 4

A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy

Terminated
NCT03798600

Pharmacokinetics/Pharmacodynamics (PK/PD) of Caspofungin in Intensive Care Unit (ICU) Patients. An Open Observational Study for Antifungal Treatment's Optimization

Completed
NCT01165320Phase 2

A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)

Completed
NCT02856178Phase 1

Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients

Withdrawn
NCT01062165Phase 4

Effect of Weight and/or Obesity on Caspofungin Drug Concentrations

Completed
NCT01994096Phase 4

Optimal Dosage of Caspofungin in Critically Ill Patients

Completed

Drug Details

Intervention Type
DRUG
Total Trials
36